Literature DB >> 36105341

Inhibitors of Transforming Growth Factor Beta Receptor 1 (TGFβr1) May Enhance the Efficacy of Several Monoclonal Antibodies as Cancer Therapy.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2022        PMID： 36105341      PMCID： PMC9465859          DOI： 10.1021/acsmedchemlett.2c00356

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  CTLA4 antagonists in phase I and phase II clinical trials, current status  and  future perspectives for cancer therapy.

Authors:  Bartosz Szostak; Filip Machaj; Jakub Rosik; Andrzej Pawlik
Journal:  Expert Opin Investig Drugs       Date:  2018-12-30       Impact factor: 6.206

2.  A Tumor-Localized Approach to Bypass Anti-4-1BB Immuno-Toxicity.

Authors:  Tina Tianjiao Su; Xiaobin Gao; Jun Wang
Journal:  Clin Cancer Res       Date:  2019-07-31       Impact factor: 12.531

Review 3.  Tgf-beta type I receptor (Alk5) kinase inhibitors in oncology.

Authors:  Leona E Ling; Wen-Cherng Lee
Journal:  Curr Pharm Biotechnol       Date:  2011-12       Impact factor: 2.837

Review 4.  Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development.

Authors:  Pottayil G Sasikumar; Murali Ramachandra
Journal:  Front Immunol       Date:  2022-05-02       Impact factor: 8.786

Review 5.  OX40 agonists for cancer treatment: a patent review.

Authors:  Jorge Cebada; Martin Perez-Santos; Cindy Bandala; Eleazar Lara-Padilla; Irma Herrera-Camacho; Nora Hilda Rosas-Murrieta; Lourdes Millán-Pérez Peña; Eduardo Monjaraz; Amira Flores; Maricruz Anaya-Ruiz
Journal:  Expert Opin Ther Pat       Date:  2020-10-06       Impact factor: 6.674

Review 6.  Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy.

Authors:  Nicholas P Tschernia; James L Gulley
Journal:  BioDrugs       Date:  2022-03-30       Impact factor: 7.744
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.